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Summary Ras/p21 oncoprotein expression and K-ras mutations were analysed by Western blot and/or K-rasoligonucleotide hybridization in
78 primary ovarian cancers, 20 omental metastases, two low malignant potential tumours (LMP), nine benign ovarian tumours and 10 normal
ovaries. A cut-off value of an integral of absorbance (i.a.) of2.20, obtained by receiveroperating characteristic (ROC) curve, was shown to be
the best cut-off for defining p21 positivity. p21 levels were higher in malignant tumours than in benign tumours (median 2.10 i.a. vs median
1.22 i.a.; P= 0.014) and in omental metastases than in primary ovarian carcinomas (median 2.54 i.a. vs median 2.1 i.a.; P= 0.0089). p21
overexpression did not correlate with any of the clinicopathological parameters examined. Follow-up data were available for 63 patients.
A significant relationship was shown between p21 positivity and a shorter overall survival (OS) (P< 0.03) and progression-free survival (PFS)
(P< 0.03). In multivariate analysis only the presence of ascites, p21 levels and epidermal growth factor receptor status retained an
independent prognostic role. K-ras gene mutations were frequently detected in benign and low malignant potential tumours (71.4%), which
were mostly mucinous (P= 0.0152).
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The prognostic characterization of patients with ovarian cancer,
which is at present based mostly on stage, volume of residual
tumour mass after cytoreductive surgery and presence or absence
of ascites (as defined by the International Federation of
Gynecology and Obstetrics, FIGO), is still inadequate. After
optimal surgical debulking and apathologically complete response
(CR) toprimary chemotherapy, tumour will recurandlead to death
in about 50% of patients (Copeland and Gershenson, 1986).
Therefore, the identification of new biological factors that are
more closely related to tumour cell biology and aggressiveness
may help to permit the prompt identification of patients with a
particularly poor prognosis.
Several studies have already shown that genetic alterations may
lead to uncontrolled proliferation by activating oncogenes or inac-
tivating tumour-suppressor genes. The most extensively studied
oncogenes in the former group include cellular ras proto-onco-
genes, which are involved in the control ofcell growth and prolif-
eration and, in the activated form, are associated with cell
transformation and induction of metastasis (Egan et al, 1987,
1989; Caulin et al, 1996). The ras family consists of three
members, N-, H- and K-ras, which code for highly homologous
proteins with a molecular weight of 21 kDa and are believed to
function as signal switch molecules. In the active GTP-bound
conformation, they transmit a signal to an effector molecule, thus
leading to cell proliferation. The transforming potential ofp21 has
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been related mainly to point mutations that are usually found in
codons 12, 13 and 61.
Many studies have demonstrated that ras molecular alterations
may prove useful in predicting the clinical behaviour of some
malignancies, including breast (Bland et al, 1995), lung (Rosell et
al, 1993) and endometrial (Mizuuchi et al, 1992) cancer. In partic-
ular, overexpression of the ras/p21 oncoprotein in breast cancer
appears to be significantly correlated with advanced tumour stage
and axillary lymph node involvement, suggesting that increased
p21 expression is associated with tumour progression and poor
prognosis. Ras overexpression is thought to be a common occur-
rence in ovarian cancer (Slamon et al, 1984; O'Brien et al, 1989),
although its prognostic role is still controversial (Rodenburg et al,
1988; Scambia et al., 1993a; Katsaros et al, 1995). In a previous
study, we reported the association of p21-enhanced expression
with the malignant phenotype and the acquisition of metastatic
potential in ovarian cancer (Scambia et al, 1993a). Because ofthe
small number of cases examined and the short follow-up, only a
preliminary evaluation of the prognostic value of p21 was then
possible.
In this study, the role ofp21 protein as a new prognostic factor in
epithelial ovarian cancer was investigated forthefirst time on a large
single-institution patient population with along-term follow-up. The
correlation between p21 levels and the presence of epidermal
growth factor receptor (EGFR), which has been reported to be
associated with a poor prognosis in ovarian cancer (Scambia et al,
1992, 1995; Bartlett et al, 1996), was also examined. Moreover, in
order to investigate whether ras gene mutation assessment could
improve the prognostic information provided by p21 oncoprotein
levels, mutations of Kras - the ras gene prevalently mutated in
ovarian tumours (Enomoto et al, 1990; Teneriello et al, 1993) -
were studied in the same population.
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MATERIALS AND METHODS
Samples
All the specimens analysed in this study were obtained from
patients undergoing surgery between 1988 and 1991 at the
Department of Obstetrics and Gynecology of the Catholic
University, Rome.
A total of 109 specimens were analysed for K-ras mutation
and/or p21 overexpression. They included 78 primary malignant
tumours, 20 omental tumours, nine benign and two low malignant
potential tumours (LMP). Normal term placentas and 10 normal
ovaries from patients with uterine fibromatosis were also
analysed. Representative tissue samples were processed for
histopathological evaluation as either frozen sections or formalde-
hyde-fixed paraffin-embedded sections to ensure that they
contained mostly cancer tissues. Histological classification of
tumours was carried out according to the World Health
Organization (WHO) system. The clinical stage of the disease
was established according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system. Patients with
stage I or II disease underwent complete staging laparotomy,
including radical pelvic and para-aortic lymphadenectomy
(Benedetti Panici et al, 1991). Chemotherapy was instituted 2-3
weeks after surgery. All patients received cisplatin-containing
regimens (Benedetti Panici et al, 1993).
Gynecological examination, abdominopelvic ultrasonography,
CA 125 assay and radiological investigations, if necessary, were
performed monthly for the clinical assessment of response, which
was recorded according to WHO criteria (WHO, 1979). About 28
days after the last course, clinically complete responders under-
went second-look laparoscopy. In laparoscopy-negative cases,
second-look laparotomy was performed for the assessment of
pathological response. During laparotomy and after peritoneal
washings and careful inspection ofthe abdominal cavity, biopsy of
all suspicious lesions was performed, along with several random
biopsies. Patients who had had initially only an explorative laparo-
tomy underwent a second laparotomy after chemotherapy, and a
second cytoreduction was attempted. Pathologically complete
responders received no further therapy, and all the other patients
were treated according to ongoing phase II studies (Benedetti
Panici et al, 1990).
incubated at 4°C in the same buffer containing Y13-259 mono-
clonal antiserum (Oncogene Science, New York, NY, USA)
(diluted 1:300) for 4 h, with rabbit anti-rat IgG (diluted 1:500) for
2.5 h and finally with Sx 106 c.p.m. ml- ['251]protein A for 1 h.
MAb Y13-259 is a rat-derived monoclonal antibody directed
against Harvey murine sarcoma virus (Ha-MSV)-encoded p21 and
reacts with both the point-mutated and normal products of the ras
gene family (H-,N-,K-ras). Filters were exposed to Kodak XAR
films (Eastman Kodak, Rochester, NY, USA) for 48 h at -80°C.
Computer-aided image analysis ofautoradiographs was performed
to quantify the intensity of the bands. A p21 control derived from
normal rat kidney cells transformed by Ha-MSV was included in
all experiments.
Densitometric values of the band intensities, expressed as inte-
gral ofabsorbance (i.a.), were used for statistical analysis. In a few
cases, Western blot analysis was performed in different specimens
of the same tumour sample to determine the intratumour homo-
geneity ofp21 expression (coefficient ofvariation 18%).
To correlate the expression of p21 with survival data, an i.a. of
2.20 was shown by the receiver operating characteristic (ROC)
curve (Hanley and McNeil, 1982) to be the best cut-off value for
defining p21 status (data not shown).
DNA preparation
Tumour specimens were stored at -70°C until analysis. Genomic
DNA extraction from fresh tissue was performed following stan-
dard procedures (Sambrook et al, 1989). If fresh material was not
available, DNA was extracted from paraffin-embedded sections
(28 cases). DNA preparation from paraffin-embedded tissues was
performed by incubating 10-jm-thick sections in 0.5 ml of a
buffer containing 10 mM Tris pH 8.3, 50 mm potassium chloride,
1.5 mm magnesium chloride, 100 jig ml' BSA, 1% Tween 20,
0.45% Nonidet P-40 and 100 jg ml' proteinase K at 55°C for
16 h. The samples were then boiled for 5-10 min and cooled on
ice. Five microlitres of a 1:10 dilution were used for polymerase
chain reaction (PCR).
Polymerase chain reaction
The following primers were used to examine codons 12, 13 and 61
of K-ras:
Detection of p21 protein
Tumour specimens were stored at -70°C until analysis. Frozen
samples were pulverized and homogenized with five volumes of
ice-cold buffer containing 20 mm Tris-HCl, 100 mm sodium
chloride, 5 mm magnesium chloride, 1% Nonidet-P40, 0.5%
sodium deoxycholate and 2 kallikrein inhibitor units per ml of
bovine aprotinin. The homogenate was centrifuged at 750 g for 20
min at 4°C, and the resulting supernatants were frozen at -80°C
before using. Protein concentration was determined by the method
of Bradford (1976) with Kabi solution (10% human albumin) as a
standard: 100 jg of each sample were separated by 12% sodium
dodecyl sulphate (SDS) polyacrylamide gel electrophoresis, trans-
blotted onto nitrocellulose filters and processed essentially as
described (Scambia et al, 1993a). Briefly, filters were incubated
for 3 h at 37°C in TEN-NP40 buffer (50 mm Tris-HCl, pH 7.5,
2 mm EDTA, 150 mm sodium chloride, 0.1% Nonidet-P40) with
3% bovine serum albumin (BSA). Then the filters were sequentially
K-ras (KA12/13):
K-ras (KB12/13):
K-ras (KA61):
K-ras (KB61):
5'-GACTGAATATAAACTTGTGG-3'
5'-CTATTGTTGGATCATATTCG-3'
5'-TTCCTACAGGAAGCAAGTAG-3'
5'-CACAAAGAAAGCCCTCCCCA-3'
PCR analysis was performed in the presence of 0.5 jig of
genomic DNA template, following the manufacturer's recommen-
dations (Gene Amp, Perkin Elmer, Branchburg, NJ, USA). The
analysis was carried out in a thermal cycler (Perkin-Elmer/Cetus
9600) for 35 cycles. Each cycle consisted of denaturation at 94°C
for 30 s, annealing at 55°C for 30 s and extension at 72°C for
1 min. The products were analysed by electrophoresis on 2%
agarose gels.
Oligonucleotide hybridization
A 15-ml aliquot of each PCR product was transferred to a nylon
filter (NEN Dupont, Bad Homburg, Germany) using a slot-blot
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minifold apparatus (Schleicher and Schuell, Dassel, Germany) and
hybridized with a panel of 20-mer synthetic oligonucleotide
probes (Mutalyzer Probe Panel, Clontech, Palo Alto, CA, USA).
These probes are representative of the normal codons 12, 13 and
61 ofK-ras as well as ofall possible activating mutations affecting
each of these codons. Oligonucleotides were labelled with
[y-32P]ATP (NEN Dupont; specific activity 3000 Ci mmol-') by
means of T4 polynucleotide kinase (Boehringer Mannheim,
Mannheim, Germany) and purified through Chroma Spin columns
(Clontech, Palo Alto, CA, USA). The filters were prehybridized
for 30 min at 37°C in 20 x SSPE, 200 mm sodium pyrophosphate,
50 x Denhardt's and 20% SDS. One pmole of the probe was then
added (1 x 106 c.p.m. ml-') and hybridization was continued at the
same temperature for 16 h.
The filters were washed in 3 M tetramethylammonium chloride
(Wood et al, 1985). Autoradiography was performed at-80°C for
1 h using Konica AX films (Konica, Tokjo, Japan).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 S
p21-
97.4 kDa
66.2 kDa
42.7 kDa
31.0 kDa
21.5 kDa
14.4 kDa
Figure 1 Western blot showing ras p21 expression in four omental
metastases (lanes 1-4), four benign tumours (lanes 5-8) and seven primary
ovarian cancers (lanes 9-15). Lane S, molecular weight standards (Biorad,
low range)
EGFR and DNA ploidy evaluation
Radioreceptorial assessment of EGFR expression was performed
on 68 primary ovarian cancers as described by Scambia et al
(1992). An EGFR level of 1.5 fmol mg-' protein was chosen as the
cut-off value to define EGFR status. DNA ploidy was evaluated
using an Epics XL cytofluorimeter as previously described
(Scambia et al, 1993b).
Statistical analysis
The Mann-Whitney non-parametric test was used to analyse the
distribution of p21 levels in primary ovarian cancer, omental
metastasis and benign ovaries. Fisher's exact test for proportion
and theX2 test were used to analyse the distribution ofp21-positive
cases according to clinicopathological characteristics. Medians
and life tables were computed using the life table method of
Kaplan and Meier (1958), and the curves were examined by means
of the log-rank test (Mantel, 1966). Multivariate analysis was
performed according to the Cox proportional hazards model with
backward stepwise procedure (Cox, 1972). Progression-free
survival (PFS) and overall survival (OS) were calculated from the
date offirst surgery to the date of clinical or pathological progres-
sion or death. Survival analyses were carried out using SPSS for
MS Windows 6.0.
RESULTS
Western blot analysis
The level of expression of p21 was analysed by Western blot in a
group of 68 primary ovarian cancers, 20 omental metastases, two
LMP tumours and nine benign tumours (Figure 1). p21 levels were
significantly higher in malignant than in benign tumours (median
2.10 i.a., range 0.12-5.00 vs median 1.22 i.a., range 0.32-2.05;
P < 0.03). A statistically significant difference was found in p21
levels of omental metastases with respect to primary ovarian
tumours (median 2.54 i.a., range 0.55-5.72 vs median 2.10 i.a.,
range 0.12-5.00; P < 0.01).
The distribution ofp21 levels according to the clinicopatholog-
ical parameters of68 primary ovarian cancers is shown in Table 1.
p21 levels were not significantly related to any of the parameters
examined; however, undifferentiated and stage IV tumours tended
to have a higher percentage ofp21 positivity. No relationship was
found between p21 overexpression and EGFR status or DNA
ploidy.
Detection of point mutations
A total of78 primary ovarian cancers, 12 omental metastases, two
LMP and five benign tumours were screened for the presence of
mutations in the K-ras gene using synthetic oligonucleotide probes
after a PCR amplification step (Figure 2). In six cases, both the
omental metastasis and the corresponding primary ovarian tumour
were analysed. Two normal term placentas were used as negative
controls. In three cases, the ovarian cancer was bilateral and both
the affected ovaries were analysed.
Of 78 ovarian cancers examined, five were found to contain ras
gene mutations (6.4%), four in codon 12 and one in codon 13.
Three were G-*C transversions and two G->T transversions
(Table 2).
Interestingly, all three ovarian cancer samples carrying the same
G-C transversion and analysed for both p21 expression and
K-ras mutation showed p21 overexpression. No data on p21
expression were available forthe othertwocases withras mutations.
No point mutations ofcodon 12, 13 and 61 were detected in any
of the 12 omental metastases or in any of the six corresponding
primary tumours.
Ras gene mutations were also analysed in LMP and benign
ovarian tumours. Both LMP tumours were mutated (100%) at
codon 13 and carried the same mutation (G-4A transition).
Activating ras mutations were also found in three of five benign
tumours (60%), all in codon 12. Two were G-*T transversion and
one G-4C transversion.
Considering the overall population analysed, mutations in K-ras
were observed in three of five (60%) mucinous tumours, 5 of 50
(10%) serous tumours, and 2 of 22 (11%) endometrioid tumours.
The higher percentage of mutations found in the mucinous histo-
type was statistically significant (P = 0.0152). Ras gene point
mutations were not differently distributed in relation to the other
clinicopathological parameters.
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Table 1 Distribution of p21 levels in 68 ovarian carcinomas according to patient characteristics
Number Median Range No. (%) of p21- P-value
of cases (i.a.) (i.a.) positive cases (x2)
Histology
Serous 47 2.02 0.3-5 24 (51) NV
Mucinous 4 1.66 1.1-1.8 0
Endometrioid 8 2.1 1.19-3.33 5 (62)
Undifferentiated 7 2.67 1.97-3.66 5 (71)
Others 2 1.19 0.12-2.27 1(50)
Stage
It1a0 1.86 0.5-3.23 3(30) 0.05a,b
11 4 1.48 1.1-3.1 1 (25)
III 47 2.1 0.12-5.00 25 (53)
IV 7 2.71 1.97-3.66 6 (86)
Grade
1-2 17 1.57 0.3-3.3 6 (35) 0.10
3 51 2.14 0.12-5 29 (57)
Ascites
No 27 2.10 0.12-3.40 14 (52) 0.57
Yes 41 2.10 0.36-5 21(51)
Residual tumour
< 2 cm 52 2.11 0.12-5 26 (50) 0.44
>2cm 16 2.58 0.36-3.66 9 (56)
Response to chemotherapy
CR-PR 47 2.11 0.12-5 25 (53) 0Q34a,c
NC-P 11 2.7 0.5-3.66 7 (64)
EGFR status
. 1.5 fmol 33 2.27 0.2-5.72 21 (63) 0.15
> 1.5fmol 35 1.85 0.3-5 14 (40)
Ploidy
Euploid 21 2.5 0.66-3.66 13 (61) 0.39
Aneuploid 28 2.43 0.5-5.72 20 (71)
aCalculated by Fisher's exact test for proportion. bl-1l vs III-IV stage. cCalculated only for stage 11 to IV.
response; NC-P, no change-progression.
Survival analysis DISCUSSION
Follow-up data were available for 63 patients (median survival of In the present st
50.31 months). During the follow-up period, 33 patients died of report on the prn
disease. When patients were divided according to the cut-offvalue ovarian cancer (
i.a. 2.20 obtained by ROC curve (Hanley and McNeil, 1982), 34 shown to be a ne
patients (54%) were p21-negative and 29 patients (46%) p21-posi- lated by multivari
tive. Figure 3 shows the OS according to p21 status. A statistically sion with poor 4
significant association was found between p21 positivity and factors, such as re
shorter OS. Patients with p21-negative tumours had a median previous studies t
survival of59 months, whereas p21-positive patients had a median levels and progre
survival of20 months (P < 0.03). et al, 1994; Blan
Figure 4 shows the PFS according to p21 status. Patients with increase in p21 le
p21-negative tumours had a median PFS of 35 months, whereas are also consisten
p21-positive patients had a median PFS of 16 months (P < 0.05). related to tumour
The relative risk of death was estimated in both univariate and that activated raw
multivariate analysis using a backward stepwise procedure. In the (Egan et al, 1987
univariate analysis, advanced stage, presence ofascites, p21 status embryo fibroblasi
and EGFR status were significantly related to shorter OS. In the become highly m
multivariate analysis, only the presence of ascites, EGFR status might be mediate
and p21 overexpression retained an independent negative prog- which are thoug]
nostic role (Table 3). (Garbisa et al, 19
NV, not valuable. CR-PR, complete response-partial
tudy, which updates and extends our previous
ognostic significance of ras/p21 expression in
Scambia et al, 1993a), p21 overexpression is
Igative independent prognostic factor. As calcu-
iate analysis, the association of p21 overexpres-
survival was independent of other prognostic
esidual disease and stage. This is consistent with
that found an association between increased p21
ssion and poor prognosis in breast cancer (Giai
Id et al, 1995). Moreover, our data showing an
evels in metastases compared with primary sites
it with the hypothesis that p21 overexpression is
aggressiveness. Several studies have suggested
Ls may contribute to the metastatic phenotype
'; Caulin et al, 1996). Transfection of normal rat
,ts with activated c-H-ras caused these cells to
etastatic (Thorgeirsson et al, 1985). This effect
-d by the induction of cellular metalloproteases,
,ht to be important in tumour metastasization
)87). Moreover, we have previously shown that
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Figure 3 Overall survival according to p21 status in 63 primary ovarian
tumours. p21 positive: 29 entered, 19 died; p21 negative: 34 entered,
15 died. Log-rank test = -1.93, P< 0.03
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Figure 2 Slot blot analysis of mutations in codons 12 to Ala (A) and 13 to
Asp (C) of Kras. The arrows in A indicate the positive and negative control.
B and D are the corresponding control blots hybridized with the wild-type
sequence
Figure 4 Progression-free survival according to p21 status in 63 primary
ovarian cancer patients. p21 positive: 29 entered, 20 progressed;
p21 negative: 34 entered, 18 progressed. Log-rank test = -1.81, P < 0.05
Table 2 Patients with ovarian tumours containing activated K-ras gene.
Patient Codon Mutation p21 level Histology Age (years) Stage Grade Ascites Residual tumour (cm)
CU 0119 12 GGT-*GTT - Serous carcinoma 34 1 1 No <2
CU 0036 13 GGC-)GTC - Serous carcinoma 45 III 3 Yes <2
CU PfOl 12 GGT-4GCT 3.33 Endometrioid carcinoma 56 IV 3 Yes <2
CU PfO2 12 GGT-*GCT 3.57 Serous carcinoma 43 III 3 Yes <2
CU PfO3 12 GGT->GCT 2.1 Serous carcinoma 39 3 No <2
CU 0031 13 GGC-*GAC 1.1 Mucinous LMP 46 11 2 No <2
CU 0053 13 GGC-+GAC 1.8 Mucinous LMP 49 NA No
CU 0004 12 GGT-4GTT 1.26 Serous adenocarcinoma 43 -
CU 0020 12 GGT-*GTT 1.20 Mucinous adenocarcinoma 21 - - -
CU 0069 12 GGT-*GCT 2.05 Endometrioid adenocarcinoma 59
NA, not available.
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Table 3 Univariate and multivariate analysis of overall survival in patients
with primary ovarian cancer.
Univariate Multivariate
RR, P-value RR2 P-value
Stage
I-11 1a
III-IV 2.50 NS - -
Grade
1-2 1a
3 1.67 NS - -
Ascites
No 1a 1a
Yes 2.01 <0.05 1.59 <0.05
Residual tumour
<2cm 1a
>2 cm 1.40 NS - -
p21 status
<2.20 i.a. 1a 1a
>2.20 i.a. 2.20 <0.05 1.43 <0.05
EGFR status
<1.5 fmol 1a 1a
>1.5 fmol 2.96 <0.01 1.80 <0.01
aReference category. RR unadjusted relative risk; RR2 adjusted relative risk,
taking into account all the factors of the table. NS, not significant.
ras expression is inversely correlated with the expression of the
NM-23 protein, which is believed to play an important role in the
suppression of metastases (Scambia et al, 1996).
Our results partly differ from two previous immunohistochem-
ical studies (Rodenburg et al, 1988; Yaginuma et al, 1992) that
found no correlation between p21 levels and clinical outcome but
are in agreement with recent work by Katsaros et al (1995),
performed by immunoblot analysis. This discrepancy may be due
to the different methods employed and the use of different mono-
clonal antibodies - RAP-5 (Rodenburg et al, 1988) and RAP-28
(Yaginuma et al, 1992) - from the one (Y13-259) used both in our
study and in that of Katsaros. RAP-5 binds to proteins of a variety
of molecular weights in many different neoplastic and normal cell
types, while Y13-259 does not recognize ras-related proteins and
is ofproven specificity to p21 ras (Robinson et al, 1986). RAP-28
recognizes epitopes shared by H-ras and K-ras gene products, but
not by N-ras-coded p21, whereas Y13-259 recognizes the epitope
shared by all the activated ras gene family (Kuzumaki et al, 1986).
It is also worth noting that Yaginuma's study (1992) included only
29 patients, 14 of which were at stage I disease. The survival of
these early stage patients was only 50% at 5 years, which would
suggest that staging procedures were incomplete.
Although in other malignant neoplasms K-ras mutations are
relatively frequent (Forrester et al, 1987; Liu et al, 1987; Bos,
1989) our data indicate that they are a rare event in ovarian
carcinomas. This finding is in agreement with previous studies
reporting a combined incidence of K-ras mutations of 4-14% in
ovarian carcinomas (van't Veer et al, 1988; Enomoto et al, 1990,
1991; Teneriello et al, 1993). The frequency of K-ras mutations is
particularly low in the most frequent serous histotype. On the other
hand, even in the small series analysed, K-ras mutations are a
frequent event in the less common mucinous carcinomas and in
benign and LMP mucinous tumours. This finding, which is in line
with previously reported data (Enomoto et al, 1990; Mok et al,
1993; Teneriello et al, 1993; Cuatrecasas et al, 1996), strongly
suggests that K-ras activation plays an essential role as an early
genetic alteration in the pathogenesis of mucinous ovarian
tumours irrespective of their malignancy. The overall low inci-
dence of ras mutations and ras amplification (van't Veer et al,
1988; Boltz et al, 1989) and the lack of correlation between ras
overexpression and genomic instability (evaluated as aneuploidy)
do not account for the high frequency of ras/p21 overexpression
that we observed. Further investigations on the mechanism
responsible for ras 21 overexpression will be required to address
this issue.
It has been reported (Satoh et al, 1990; Dickson et al, 1987) that
ras/p21 is involved in the intracellular pathway through which the
EGF mitogenic signal is transduced. Moreover, high levels of
EGFR are associated with a particularly poor prognosis in ovarian
cancer (Scambia et al, 1992; Bartlett et al, 1996). Our data show
that both ras overexpression and EGFR are independent prog-
nostic parameters. Therefore, it is possible that the simultaneous
evaluation of both EGFR and ras may provide complementary
information about the presence of alterations of the ras/p21
pathway at different steps, thus improving the prognostic charac-
terization ofovarian cancer patients.
In conclusion, the data presented in this study suggest that the
assessment of p21 status at the time of initial surgery may allow
the identification of a subset of patients with a particularly poor
prognosis. High-risk patients could be candidates for more aggres-
sive and/or experimental primary treatment than that convention-
ally used. Furthermore, the prognostic significance of p21 levels
might imply that ovarian cancer is a candidate for a novel anti-
cancer therapy based on drugs targeted directly against ras activity.
Progress has already been made in the development of famesyl-
transferase inhibitors which block ras famesylation and abolish
ras-transforming activity 'in vitro' (Gibbs et al, 1994) and the
growth ofras-dependent tumours in nude mice (Kohl et al, 1994).
Therefore, it would be of interest to test such compounds in
patients with ovarian carcinoma overexpressing ras/p21.
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